Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

74 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Randomized phase I trial of antigen-specific tolerizing immunotherapy with peptide/calcitriol liposomes in ACPA+ rheumatoid arthritis.
Sonigra A, Nel HJ, Wehr P, Ramnoruth N, Patel S, van Schie KA, Bladen MW, Mehdi AM, Tesiram J, Talekar M, Rossjohn J, Reid HH, Stuurman FE, Roberts H, Vecchio P, Gourley I, Rigby M, Becart S, Toes RE, Scherer HU, Lê Cao KA, Campbell K, Thomas R. Sonigra A, et al. Among authors: gourley i. JCI Insight. 2022 Oct 24;7(20):e160964. doi: 10.1172/jci.insight.160964. JCI Insight. 2022. PMID: 36278483 Free PMC article. Clinical Trial.
First-in-Human Study in Healthy Subjects with FR104, a Pegylated Monoclonal Antibody Fragment Antagonist of CD28.
Poirier N, Blancho G, Hiance M, Mary C, Van Assche T, Lempoels J, Ramael S, Wang W, Thepenier V, Braudeau C, Salabert N, Josien R, Anderson I, Gourley I, Soulillou JP, Coquoz D, Vanhove B. Poirier N, et al. Among authors: gourley i. J Immunol. 2016 Dec 15;197(12):4593-4602. doi: 10.4049/jimmunol.1601538. Epub 2016 Nov 14. J Immunol. 2016. PMID: 27849166 Clinical Trial.
Drug hypersensitivity reactions: review of the state of the science for prediction and diagnosis.
Pallardy M, Bechara R, Whritenour J, Mitchell-Ryan S, Herzyk D, Lebrec H, Merk H, Gourley I, Komocsar WJ, Piccotti JR, Balazs M, Sharma A, Walker DB, Weinstock D; HESI Immuno-Safety Technical Committee, Drug Hypersensitivity Reactions Project team. Pallardy M, et al. Among authors: gourley i. Toxicol Sci. 2024 Apr 8:kfae046. doi: 10.1093/toxsci/kfae046. Online ahead of print. Toxicol Sci. 2024. PMID: 38588579
Safety and Efficacy of SBI-087, a Subcutaneous Agent for B Cell Depletion, in Patients with Active Rheumatoid Arthritis: Results from a Phase II Randomized, Double-blind, Placebo-controlled Study.
Damjanov N, Tlustochowicz M, Aelion J, Greenwald M, Diehl A, Bhattacharya I, Peeva E, Menon S, Gourley I. Damjanov N, et al. Among authors: gourley i. J Rheumatol. 2016 Dec;43(12):2094-2100. doi: 10.3899/jrheum.160146. Epub 2016 Oct 1. J Rheumatol. 2016. PMID: 27909139 Clinical Trial.
Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of SBI-087, a CD20-Directed B-cell Depleting Agent: Phase 1 Dose Escalating Studies in Patients With Either Mild Rheumatoid Arthritis or Systemic Lupus.
Cohen S, Clowse M, Pardo P, Bhattacharya I, Menon S, Gourley I, Diehl A. Cohen S, et al. Among authors: gourley i. Clin Ther. 2016 Jun;38(6):1417-1434.e2. doi: 10.1016/j.clinthera.2016.03.028. Epub 2016 Apr 21. Clin Ther. 2016. PMID: 27112532 Clinical Trial.
74 results